Srirangam Vinaya, Rai Bhavan Prasad, Abroaf Ahmed, Agarwal Samita, Tadtayev Sergey, Foley Charlotte, Lane Tim, Adshead Jim, Vasdev Nikhil
Department of Pathology, Lister Hospital, Stevenage, UK.
Hertfordshire and South Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.
Curr Urol. 2017 Nov;10(4):199-205. doi: 10.1159/000447181. Epub 2017 Oct 22.
Atypical small acinar proliferation (ASAP) and high grade prostatic intraepithelial neoplasia (HGPIN) are considered precancerous. We aimed to measure the rate of repeat biopsy and adenocarcinoma in patients with ASAP and HGPIN and identify any clinico-pathologic parameters at diagnosis of ASAP/HGPIN that are predictive of adenocarcinoma.
Patients with a diagnosis of ASAP/HGPIN with no previous or concomitant cancer were identified. Prostate specific antigen (PSA) and magnetic resonance imaging (MRI) changes were monitored. Re-biopsy was at clinician discretion.
Nineteen were diagnosed with ASAP and 17 with HGPIN. Seven with ASAP (37%) and 6 with HGPIN (35%) underwent re-biopsy. Three (16%) with ASAP and 5 with HGPIN (29%) were diagnosed with adenocarcinoma. The difference in cancer detection rates between ASAP and HGPIN was not significant (p = 0.35). Five (14%) in total required definitive therapy for adenocarcinoma. Twenty-three (64%) did not undergo repeat biopsy. Parameters at diagnosis of HGPIN and ASAP, including PSA, prostate volume and PSA density, were compared between the cancer and non-cancer cohorts with none found to be predictive of adenocarcinoma.
By monitoring PSA and MRI changes, we managed to spare re-biopsy in two-thirds of patients. Further evaluation is necessary to characterize a surveillance protocol in these populations.
非典型小腺泡增生(ASAP)和高级别前列腺上皮内瘤变(HGPIN)被视为癌前病变。我们旨在测量ASAP和HGPIN患者的重复活检率和腺癌发生率,并确定在诊断ASAP/HGPIN时可预测腺癌的任何临床病理参数。
确定诊断为ASAP/HGPIN且既往无癌症或同时无其他癌症的患者。监测前列腺特异性抗原(PSA)和磁共振成像(MRI)的变化。重复活检由临床医生决定。
19例诊断为ASAP,17例诊断为HGPIN。7例ASAP患者(37%)和6例HGPIN患者(35%)接受了重复活检。3例ASAP患者(16%)和5例HGPIN患者(29%)被诊断为腺癌。ASAP和HGPIN之间的癌症检出率差异无统计学意义(p = 0.35)。共有5例(14%)因腺癌需要确定性治疗。23例(64%)未接受重复活检。对HGPIN和ASAP诊断时的参数,包括PSA、前列腺体积和PSA密度,在癌症组和非癌症组之间进行了比较,未发现任何参数可预测腺癌。
通过监测PSA和MRI变化,我们成功避免了三分之二患者的重复活检。有必要进行进一步评估以明确这些人群的监测方案。